Ceribell's Senior VP Foehr Sells 866 Shares at $11.71 on 2023-08-27.

Ceribell, Inc. [CBLL] has announced that Foehr David, Senior Vice President of Finance and PAO, has sold 866 shares at a price of $11.71 per share on August 27, 2025.

Ceribell, Inc. [CBLL], a company focused on transforming the diagnosis and management of patients with serious neurological conditions, has seen significant insider trading activity. On August 27, 2025, Foehr David, Senior Vice President of Finance and PAO, sold 866 shares of the company's stock at a price of $11.71 per share [1].

This transaction follows a series of insider sales that have occurred over the past few months. On July 11, 2025, the company's CEO, Chao, sold 25,000 shares of CBLL stock, and on June 21, 2025, a director sold $131,255.35 worth of shares [2].

Ceribell's stock has been the subject of recent positive sentiment, with analysts giving the company a consensus recommendation of "Buy" and a $32.14 consensus price target [3]. However, the company is currently facing a patent infringement claim from Natus Medical. Natus Medical has filed a response denying the claim, stating that its BrainWatch system does not infringe upon CeriBell's patents [4].

Despite the legal challenges, Ceribell continues to attract investments. TimesSquare Capital Management LLC invested $10.31 million in the company in July 2025, and Bank of America Corp DE Invested $498,000 in June 2025 [5].

References:
[1] https://www.stocktitan.net/sec-filings/CBLL/form-4-ceri-bell-inc-insider-trading-activity-ab7a10833363.html
[2] https://www.marketbeat.com/stocks/NASDAQ/CBLL/news/
[3] https://www.marketbeat.com/stocks/NASDAQ/CBLL/news/
[4] https://www.massdevice.com/natus-medical-denies-ceribells-brain-eeg-patent-infringement-claim/
[5] https://www.marketbeat.com/stocks/NASDAQ/CBLL/news/